Anticancer Therapeutics

Description: Written by the winner of the 2008 Mike Price Fellowship

"This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject." Anticancer Research, November – December 2008

This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today’s multidisciplinary approach to cancer treatment.

Clearly structured throughout, the book not only provides information on currently used molecular treatment approaches, but also describes the various agents that are currently at various stages of development and clinical trials, thus making them the drugs of tomorrow.

The book goes on to present current therapeutic regimes including their indications and side effects, as well as their position in the international market in terms of sales and development costs. Furthermore, coverage of our advancement in the understanding of cancer biology and how this has driven the drug discovery process is clearly discussed. Modern drug discovery aspects, through genomic, proteomic and metabolomic approaches are referred to as well as combinatorial chemistry techniques and discovery of chemotherapeutic agents from plant extracts, re-use of old drugs and drugs from other indications, or de novo rational drug design.

Including contributions from leading experts in the field, this book provides the reader with a complete overview of the various types of therapeutic agents, current and emerging, as well as other aspects associated with anticancer therapy, drug design, resistance and clinical trials in oncology.

Contents:

Contributors.

Preface.

SECTION I: DEVELOPMENT OF ANTICANCER THERAPEUTICS.

1. Exploring the potential of natural products in cancer treatment (Fotini N. Lamari and Paul Cordopatis).
   1.1 Introduction.
   1.2 Sources.
   1.3 Different approaches to the search for bioactive natural products.
   1.4 Methodologies of lead compound or new drug identification.
   1.5 Chemoprevention – a new area for natural product research.
   1.6 Concluding remarks.

2. Combinatorial approach to anticancer drug design (Sotiris MIsailidis).
   2.1 Introduction.
   2.2 Combinatorial approaches for small molecule drug design.
   2.3 Display technologies.
   2.4 Aptamer selection.
2.5 Conclusions.

3. Rational approaches to anticancer drug design/in silico drug development (Stefano Alcaro, Anna Artese and Francesco Ortuso).

3.1 Introduction.

3.2 Approaches to the drug discovery process in anticancer research.

3.3 Ligand-based examples.

3.4 Structure-based examples.

3.5 Conclusions.

SECTION II: ANTICANCER THERAPEUTICS.

4. Introduction (Teni Boulikas).

4.1 Introduction.

4.2 Problems in cancer.

4.3 Cancer treatments.

4.4 Classification of chemotherapy drugs.

5. Platinum drugs (Teni Boulikas, Alexandros Pantos, Evagelos Bellis and Petros Christofis).

5.1 Cisplatin.

5.2 Lipoplatin.

5.3 Carboplatin.

5.4 Oxaliplatin.

5.5 Lipoxal.

5.6 New platinum compounds.

5.7 Cisplatin resistance and chemotherapy.


6.1 Taxanes.

6.2 Vinca alkaloids.

6.3 Conclusions.

7. Antimetabolites in cancer therapy (Jessica Scaiffe and David Kerr).

7.1 Introduction.

7.2 Folate antagonists.

7.3 Pyrimidine antagonists.

7.4 Purine antagonists.

7.5 Summary.
8. Antitumour antibiotics (Manuel M. Paz).
8.1 Introduction.
8.2 Actinomycin.
8.3 Mitomycin C.
8.4 Bleomycin.
8.5 Anthracyclines.
8.6 Trabectedin (ecteinascidin, ET–743).
8.7 Camptothecins.
8.8 Podophyllotoxins.

9. Alkylating agents (Ana Paula Francisco, Maria de Jesus Perry, Eduarda Mendes and Rui Moreira).
9.1 Introduction.
9.2 Nitrogen mustards.
9.3 Methylmelamines and ethylenimines.
9.4 Methylhydrazine derivatives.
9.5 Alkylsulfonates.
9.6 Nitrosoureas.
9.7 Triazenes.

10.1 Introduction.
10.2 Oestrogen receptor targeted therapeutics.
10.3 Progesterone targeted therapy.
10.4 Neuroendocrine tumours.

11.1 Introduction.
11.2 Photosensitizers.
11.3 Outlook.
11.4 Acknowledgement.

12. Target–directed drug discovery (Tracey Bradshaw).
12.1 Introduction.
12.2 Tyrosine kinases – role and significance in cancer.
12.3 Targeted therapy for the treatment of non–small cell lung cancer.
12.4 Targeted therapy for the treatment of chronic myeloid leukaemia.
12.5 Targeted therapy for the treatment of breast cancer.
12.6 Angiogenesis.
12.7 Targeting cell cycling.
12.8 Targeting apoptosis.
12.9 Targeting mTOR.
12.10 The future of molecularly targeted therapy.

13.1 Introduction.
13.2 Hypoxia inducible factor-1 and hypoxia.
13.3 HIF-1? post-translational changes.
13.4 How genetics can modify HIF.
13.5 How tumours overcome hypoxia with HIF-1.
13.6 HIF-1 therapeutics.
13.7 Conclusion.

14. Resistance to chemotherapy drugs (Robert O’Connor and Laura Breen).
14.1 Introduction.
14.2 What are the factors limiting the efficacy of cancer chemotherapy treatment?.
14.3 A classification of the important chemotherapy resistance mechanisms.
14.4 Illustrative mechanisms of pharmacokinetic resistance.
14.5 Illustrative mechanisms of pharmacodynamic resistance.
14.6 Conclusion.

15. Cancer immunotherapy (Maria Belimezi).
15.1 The molecular basis of cancer immunotherapy and gene immunotherapy of cancer.
15.2 Recombinant monoclonal antibodies.
15.3 Gene immunotherapy.
15.4 Cancer vaccines.
15.5. Adoptive cellular therapy.

16.1 The concept of gene therapy.
16.2 Steps for successful gene therapy.
16.3 Retroviruses in cancer gene therapy.
16.4 Adenoviruses in cancer gene therapy.
16.5 Gene therapy of cancer.
16.6 Cancer immunotherapy with cytokine genes.
16.7 IL-12 in cancer immunotherapy.
16.8 Gene therapy using liposomal genes.
16.9 Viruses able to kill cancer cells.
17. Antisense agents (Huma Khan and Sotiris Missailidis).
17.1 Introduction.
17.2 Traditional antisense oligonucleotides (ASOs).
17.3 Ribozymes and DNAzymes.
17.4 RNA interference and siRNAs.
17.5 Shortcomings of antisense therapeutics.
17.6 Antisense agents in clinical trials.
17.7 Concluding remarks.
18. Aptamers as anticancer agents (Vaidehi Makwana, Suzanne Simmons and Sotiris Missailidis).
18.1 Introduction.
18.2 Aptamers in cancer.
18.3 Final comments.
SECTION III: OTHER ASPECTS IN ANTICANCER THERAPEUTIC DEVELOPMENT.
19. Treatment of cancer in conjunction with other agents (Gary Robert Smith).
19.1 Introduction.
19.2 Non-steroidal anti-inflammatory drugs.
19.3 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockade.
19.4 Partners in crime – dealing with co-infections.
19.5 Discussion.
20. Clinical trials in oncology (Tim Friede, Janet Dunn and Nigel Stallard).
20.1 Clinical trials.
20.2 Early phase (phase I and phase II) clinical trials in oncology.
20.3 Confirmatory (phase III) trials in oncology.
20.4 Further issues in clinical trials in oncology.
21. Representative cancers, treatment and market (Teni Boulikas).
21.1 Lung cancer.
21.2 Breast cancer.
21.3 Prostate cancer.
21.4 Colorectal cancer.
21.5 Ovarian cancer.
21.6 Pancreatic cancer.
21.7 Gastric cancer.
21.8 Combination chemotherapy.
21.9 The pharmaceutical world of anticancer drugs.

22. Conclusions and prospects (Sotiris Missailidis).
22.1 Cancer prevention.
22.2 Personalized medicines.
22.3 Delivery systems.
22.4 Closing remarks.

Ordering: Order Online - http://www.researchandmarkets.com/reports/2326257/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.

Product Name: Anticancer Therapeutics
Web Address: http://www.researchandmarkets.com/reports/2326257/
Office Code: SCD22DL9

Product Format
Please select the product format and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy (Hard Back): USD 184 + USD 29 Shipping/Handling</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World